N
Google TrendMICHAEL OLISE (500+) — Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:michael olise500+bank of america fine1000+club brugge200+rb leipzig200+anthony gordon500+mid atlantic ridge earthquakes500+montez sweat2000+rob lowe1000+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Biologics vs. Biosimilars" (30 stories)

Top Headline Story

Games
Lead StoryFOX 2general
1d ago

Games

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE1wUlFlbkZCYWt5eWFDQnBmY0V2S0tGQ1VLNzFGQXc3QnQtZnJreVFLQ1BvbjhabnVlTExWTUFTbnl2U1NScjZhVVBMSC1TdlU0eDNabTBLclhZdFBudEE?oc=5" target="_blank">Games</a>  <font color="#6f6f6f">FOX 2</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
500+25m ago

michael olise

Transfer Rumors: Liverpool Handed Olise Boost; Man Utd Battle Real Madrid for McTominay

Filter stories
1000+25m ago

bank of america fine

Bank of America fined $1.2 billion over money-laundering violations

Filter stories
200+25m ago

club brugge

LIVE: Dan toch 1-1! Club laat zich na penalty Tresoldi te makkelijk vangen, Lautaro zorgt voor gelijkmaker

Filter stories
200+25m ago

rb leipzig

Nach 6:0 in der Liga: Demichelis erwartet anderes Kaliber

Filter stories

Search Results for "Biologics vs. Biosimilars"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Biosimilar Bills Would Automate Medicare Negotiation Delays
Center for Biosimilarspolitics

Biosimilar Bills Would Automate Medicare Negotiation Delays

<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQRVM0RHFiNDlocHFrb0tYbzdpSHJ2d0p3VlY1YUplUXY0enEwckROTVREX2c4aThkNkV1dkdLWEIwa1dfMlRhRHpLNHhVYTlLZnZiaWV0NDhmZXBnSmNjd3JwenVTbG1TdGZINjV4elg0ak85OTU2SjFSbGRWTVBZX2E3VmdzWF82V1hMYjdCVHhnaEo3VENOV1lvVFRKNHdidzc4?oc=5" target="_blank">Biosimilar Bills Would Automate Medicare Negotiation Delays</a>  <font color="#6f6f6f">Center for Biosimilars</font>

Read Full StoryMore like this
Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA
PR Newswire Canadaworld

Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA

<a href="https://news.google.com/rss/articles/CBMi9AFBVV95cUxQWGd1RW02RUN0R3JrVlpsQklQZVFVck1odHMzc19uX0lRR1NCZlJUXzBTVFFad25xelFQS1dDVjZrVEplbGl3WE04ck40Wmx6YjBULUlhN245Q0ZJSy1LY0pobzZNOUo1MV82SnZMb3Vqd3pOYjdyRDBqTV9HbTNzMWdqdEVmR1JuQ1NsczJXYjQxUHE5X3dVR1lTdHduNk9KTC0yeXJEY2VTYlFCc24tRVBjRXBGU2RHOEg1NjE2elk2ckZET3BhaWc5a3VOR1JONExJZVVHTWdLSnJmUEZNVDdOODJyTnA4WWhMdFlldlpWOU52?oc=5" target="_blank">Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA</a>  <font color="#6f6f6f">PR Newswire Canada</font>

Read Full StoryMore like this
Biosimilars Action Plan
U.S. Food and Drug Administration (.gov)general

Biosimilars Action Plan

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE4zZmMtMUFDQWtBV3Fnd0xyRkhCWDc3NVQ0MF9FNVhuZ2ZrWTlxOVZLRGpqX0xzRWFxNGE5eHRTWVVTOXVmWGpRMnJGLUJSSnFsck9YckltdzRkWkd1c2xkT1ZHekFVU3Uxd09iTmJ3?oc=5" target="_blank">Biosimilars Action Plan</a>  <font color="#6f6f6f">U.S. Food and Drug Administration (.gov)</font>

Read Full StoryMore like this
LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity
BioPharma APACtech

LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxNaFNxRkp4V0t1Q1Z1VzRiQy1DUmJYQUNrelVqaWRmaGtTR0J2VS1YZ3ZLZnVhbWhPazd5WEtXWkIzbFFKQ2t6RVlzeHp2RUZwTm5NNVlrcVptSHBMRmo4MEdtZTQ3UkpYbGZ2ZDlHQkxLeVJ0d2VNTnRrX3BDVWxpOE1QMTdQSXpCTTVKQTdPX2NjVlZtbEJSOFladlhNMFhwSEJLb1diZWlmTGxKYWowUnEwMEg2b2QtMlVZX3V0elc2MXBmOURhSk5EZUtJc2NBeS1qMHp3bThVdHIwS2RBLWRPbVIyQQ?oc=5" target="_blank">LOTTE Biologics and Alvotech Forge Long-Term Partnership to Expand Global Biosimilar Manufacturing Capacity</a>  <font color="#6f6f6f">BioPharma APAC</font>

Read Full StoryMore like this
Perfusion for next generation biosimilars
European Biotechnology Magazinegeneral

Perfusion for next generation biosimilars

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPOFhjZVJtODJsZUl5dDVXRS1OQXpoREtqZko4U2N4UVRtbldvSTBidGRqOFYxb085U213SElqNUdlcUw5QVZKR1VmRWN6Z1JQeGZXTVdoSlJjUlZCMDBEalM3V0JMSU1wdUE4bDFBTm1mRjZWWU5sYXphejFmZFluekFBYVpfdW84cURxLTJ2X01obkRyOWRBQWJkWHBLelJXOUE?oc=5" target="_blank">Perfusion for next generation biosimilars</a>  <font color="#6f6f6f">European Biotechnology Magazine</font>

Read Full StoryMore like this
16 years later: How BPCIA continues to expand competition and lower costs
PhRMAgeneral

16 years later: How BPCIA continues to expand competition and lower costs

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxPTFc3TnZtUF9BVUVNVm5rTFBjUnlWVGdpYnBvbTBhLTF3S0kzUVB1Wjc0U2g1ektfS0dzMF90YWlhVnd6cmtTbG1aUHBRYXI1ajdmNGxEUnA1R3A2bDBqQ3pBemlIRy00eUtVd2dlbXJpSG0wX1ZkelJRWG1VUWpkMmZVRG1aSVdIVGNSOUJNTXE4VjRpMVhXQW5rNA?oc=5" target="_blank">16 years later: How BPCIA continues to expand competition and lower costs</a>  <font color="#6f6f6f">PhRMA</font>

Read Full StoryMore like this
Lower-cost alternatives to cancer drugs may cut treatment costs
Newsroom | UCLAgeneral

Lower-cost alternatives to cancer drugs may cut treatment costs

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNeXVvRHBpZFlrV3FXa3QzS0E1ZWd5ZUUxZHZhUnNTRmQyYTNxMXRzbHJEM2NkQ0pMcjZaUUNkOGM3RVptajA4UGhfWUNBUGtXUDFKNTAtZEYwNV9vcHJIZmZRNkxUN1FPUHkzcTNDT3pVSWpjUXk3RWp4ZGZtbjFEaHU3M0M3czhBOEZJOWVmcDROOUNGejBCWmc2TQ?oc=5" target="_blank">Lower-cost alternatives to cancer drugs may cut treatment costs</a>  <font color="#6f6f6f">Newsroom | UCLA</font>

Read Full StoryMore like this
Alvotech Selects LOTTE Biologics' Syracuse Plant to Make Biosimilar Antibody Drug Substance
BioPharm Internationaltech

Alvotech Selects LOTTE Biologics' Syracuse Plant to Make Biosimilar Antibody Drug Substance

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQZEZqUDZIV2liemE5VXJtU2JrcFVBczZkTzBPZ2ZQTnlacWdkbVpCLWMyWkJMYnE4Q0E4SUFIYnZDT1RnWHQ4Yy1CTjFVaTFLcGg3amZyYjE5cDRaN2EtRWVEYXU4WDIxbkEydkNXRXdyellvMTM5ck5qOVdQME9OaGpHdXdTeTBXaWRJeWFQU1FlZEZqbnF3WGpoRjRsQjhweHhlZ1g4U0lRWExRVExEcw?oc=5" target="_blank">Alvotech Selects LOTTE Biologics' Syracuse Plant to Make Biosimilar Antibody Drug Substance</a>  <font color="#6f6f6f">BioPharm International</font>

Read Full StoryMore like this
EirGenix Advances Global Biosimilar Partnerships and CDMO Strategy at BioJapan 2026
GeneOnlinegeneral

EirGenix Advances Global Biosimilar Partnerships and CDMO Strategy at BioJapan 2026

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQSE9uQ3BjRXN2OGNtQmg0dnlIOE1nRjFQZmo3MGFEN2FWUjlzQWdoZXpRTlhmV3VUdE14MGhVZW55WUxHNkV2NDVSVnpuOTdCLWZnZkRfTm9vWVBCdjZTNHJKcGtkd3pudUNTZUlPX2VCQnNLVlRFUE5fX1hNOGd5MWZUM2V0TG9sV2htVkk5ZFlkZHJJejAzalFRanVCMDJwckJkSnJyYnM5TFgzZFBPNg?oc=5" target="_blank">EirGenix Advances Global Biosimilar Partnerships and CDMO Strategy at BioJapan 2026</a>  <font color="#6f6f6f">GeneOnline</font>

Read Full StoryMore like this
Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A
JDSuprageneral

Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQNWFITXBWWnYxZHRTakM4M1dkeHFLQ2xSb290elNfYXg5YVpwc2NCYXo5eFZ0SDRfQ1BCekx3TGRxVlNZcEZ0N1R5VXFSZ0NoVGV1MWhyQ3A4UnJxTUNJQnRHMnp5TlRNaGhwUWF4X1E4YllpOXAxZjNKU3Zja0hjZWJ6QV9KWVZs?oc=5" target="_blank">Biosimilars at an Inflection Point: How Regulatory Reform, a Maturing Patent Framework and a Looming Patent Cliff Are Reshaping M&A</a>  <font color="#6f6f6f">JDSupra</font>

Read Full StoryMore like this
Biosimilars: A Guide for Pharmacists
Pharmacy Timesgeneral

Biosimilars: A Guide for Pharmacists

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE03eVVCYTVnZDhJZFlvSjQ1NldoeVBrM2RYR0ZnLWhBTXRQa1psSU1GbTEwU3VfN3NDaFpyaF9ENTFoRmJyc1ZHQ2lWNGttR3lfQkhHQ2tRS05FOFBYMFFteXBYT0pla3RsSlB3RFZrV1VxNzAxUG93SWdR?oc=5" target="_blank">Biosimilars: A Guide for Pharmacists</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability
yankton.networld

Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability

<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxQNW1EMHFkY19fUDJKd09Ec1lRcDJMZllVa3FlV0pWNXE3cWgwU2NtS2oxUWJPMDJjbk9hT2o1cEFlMFpLNDVFWDI0TWlOSDNRSlczOHQtdXNrS05nczhxMG94SGstcnVrVE43aTlWLV9ZTXZtT2E4eVB4OFp2clpyVFhha2JWS0tqT3otREIzN3VQQVpxMUtsTXQxTVVTQVNkZXhqMnhhUTk4ZndwRmc?oc=5" target="_blank">Understanding How ‘Biosimilar’ Drugs Can Expand Access and Affordability</a>  <font color="#6f6f6f">yankton.net</font>

Read Full StoryMore like this
Drugs for autoimmune diseases are pricey. This bill could switch patients to a cheaper one
CalMatterspolitics

Drugs for autoimmune diseases are pricey. This bill could switch patients to a cheaper one

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxNa0pkbmVlSGN5NHQ5OVBxVExZd3BsUUw0a3BFNWU1cVFBQU5KWkh1NlJhTG5GeGM1ZGJ1Szd5eUFPR2RnNDIyUWk3c1o4QzVaX1ZmcGIwUDJ3aVp5V3hSV2JET1hXM19WdkZSREpYTDRpV3RrRk4yck1TeVJTRkxLSzdsY2xTcVBSbVBj?oc=5" target="_blank">Drugs for autoimmune diseases are pricey. This bill could switch patients to a cheaper one</a>  <font color="#6f6f6f">CalMatters</font>

Read Full StoryMore like this
Biologics and Biosimilars Market
Yahoo Financemarkets

Biologics and Biosimilars Market

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxOY3dvc1BJWEQ3bXlzTmE0WUJsa2ZwLTUyLXFqeDRiRk1iQVhMM0FrdWhHT1ZCQjh6LXd5cXYtT2ZUNEVUbXdyYjFqc0V2clp0cFkyU2ZldWxVYXRra1luQU5iNHM1d01Pd0xSdFM3eXNkWS1ORkRyOWNjd24tTExXU0g3TFZ5WUhHSXN6ejlUdGpKN1U?oc=5" target="_blank">Biologics and Biosimilars Market</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
BioSpaceworld

Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxPeTdBbVZ4Qk5wb3lWUzRuRk9VanBpekhZZk5WLWlVcUE1WEJUZEJvUWpBYThTa1QteHcwRXl3X2pQLWF0U3JNaXZVU0FwUjlIS0tpRjJrWUNhS2cwYlo3QVRubjVCblFneFY0dXY0QjZHcmQ1STdEemduQm5PSHZ0NVN1X1l5VGczVUxWWUpPN1luUmNBZEJLQVkxQlhWMC1OWHJ3Ym9keWtrRHhzMF9jNWRTUzBxT0JYdk9Wdmk0aktJdmZnNUVocw?oc=5" target="_blank">Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate</a>  <font color="#6f6f6f">BioSpace</font>

Read Full StoryMore like this
What are biologics and can the Trump administration make them cheaper with biosimilars?
PBSgeneral

What are biologics and can the Trump administration make them cheaper with biosimilars?

<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPaUNXTXl1Z0hpUjBYa2d5VUlRQy13LUQ3aVMtM284U3l5d1cwbC0xU1N0STBXQXNMSUh6bDJNSjZXekZUUmZGTDBDdkhzVzU3V2VYNmtLYU5jYUpLaVBhejNsRU5BWlQ4a1loenFKMVRRcktCOEo5ZXJWTE9IRFRYZWc0dzFFbFhadWNzZzdyTkRoSWRYMm5tWTlzUHZzU1IyZW9CREEzcTdTTU0ycmlnRE43Y0pkZzAzVDJKV2tnOA?oc=5" target="_blank">What are biologics and can the Trump administration make them cheaper with biosimilars?</a>  <font color="#6f6f6f">PBS</font>

Read Full StoryMore like this
'Maximising off patent medicines and why the PBS needs a biosimilar strategy'
PharmaDispatchgeneral

'Maximising off patent medicines and why the PBS needs a biosimilar strategy'

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNWGZjSFg0TFZJd2NmRGJabEp4b0dTTHNDUVdSWUZGa0V5MjJoc2E3U0xlaWN0MkFOVVR4emIyTElaMUw2RGZUWjhrUWFVZ3pPQjg5d05abjZyNWRadU5zSTlZa1JBazFocHB6YXl2Qk1zNjNmVm95Q093aGI0b2tGeUpQVnR6SUszWTM5dGU3YXFXLXhoOFNYUGhWLU1ZZFZZbTM3V0tn?oc=5" target="_blank">'Maximising off patent medicines and why the PBS needs a biosimilar strategy'</a>  <font color="#6f6f6f">PharmaDispatch</font>

Read Full StoryMore like this
Representative Nicholas A. Langworthy introduces H.R. 10628: Biosimilars Access and Affordability Act
Quiver Quantitativegeneral

Representative Nicholas A. Langworthy introduces H.R. 10628: Biosimilars Access and Affordability Act

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxON2V1R3FMSlF5eHU3blZJYVlkbzQtTDI1UEQwNXRWcGoxNEFsMGkxbmhMeVlEakRCRVJtc1VDTmU3RUw4Q05Ga19fZVowMmtfQmk4elB5OG82aG1TejI1UHQ1S2xldzVoWlFza1l2Z3BBQ2NkLXg0REJOTE04ZnhMWmtuRmhJWGpsQW9HMExhZ2VoTU9nVzVxTGt2QkhPYnN4bHdOZmlpRHB3QkhuXzMwVUxVLTRIUEljeTFVeUpUQm5ERFRILUdKTWExdklIcG1wblE?oc=5" target="_blank">Representative Nicholas A. Langworthy introduces H.R. 10628: Biosimilars Access and Affordability Act</a>  <font color="#6f6f6f">Quiver Quantitative</font>

Read Full StoryMore like this
Exclusive | Cheap Biologic Drug Alternatives Stall, Threatening U.S. Healthcare Savings
WSJscience

Exclusive | Cheap Biologic Drug Alternatives Stall, Threatening U.S. Healthcare Savings

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxObXdSZkx1TDZWeVZaQXRmalpDTUFITi1pUVdCUlRPNHF1b0poR2JFbXpwUEdtRkxaZEdLQkl4WHFybEN0bm1IMU50dVFNQ2lOV01uSm4tNXVPb1hVYzAtdFFZUWJMYlEtLVl5ZDVybFRETDVnSFd2bHlpTElQa1RFbWFXSkRhSERjVUJsUjVLeWF4RlNxSGhzSWdyOWdULUF0a0pTcDNId3htemtER0xoZEd2eUtnN3M?oc=5" target="_blank">Exclusive | Cheap Biologic Drug Alternatives Stall, Threatening U.S. Healthcare Savings</a>  <font color="#6f6f6f">WSJ</font>

Read Full StoryMore like this
AAM Report: Generics and Biosimilars Saved $496 Billion in 2025
Specialty Pharmacy Continuumpolitics

AAM Report: Generics and Biosimilars Saved $496 Billion in 2025

<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQc3BEaGN3MXdCcDQ1MjFfSDVRSEZGN1h6WXExNXRfRUVWd0lTbkkxdy1Id1hVU3Z3Z2VPMDJ1S2VzU2JJaWdRM2NWcXlOeUd6QjBCcnlhN0pkUW4xcWl1UDh0MXpFX1B3TS0yaFE2cU9rUEhUTERoTnBRcUlCS0hPdjJ1LXIzalljNEhUY2dCY0V5Y3dxVFVtNXdKZ2U0Ul9oUnd2dHV1Z3ZoaXBIN2c4TzFnckR5YkJGaVZ6QWVqXzZMSlJn?oc=5" target="_blank">AAM Report: Generics and Biosimilars Saved $496 Billion in 2025</a>  <font color="#6f6f6f">Specialty Pharmacy Continuum</font>

Read Full StoryMore like this
Egypt opens country’s first EIPICO 3 biologics and biosimilars plant
Labmate Onlineworld

Egypt opens country’s first EIPICO 3 biologics and biosimilars plant

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxQNE1UQ3ctRUEtMnJHQXloLWphSWFXSTEyWTZ2R0o0RzlqNXpRM1prLW1jSlljNFRjSExjWkZBdGtLVW1OMC0zWVNualh3VFFCTG5USDNDOExwMzVpOHFkOXdLYlF1eHhmZTFELVNCNXJrM3h1a1RDYUE5Uk9KV0NUMTdySi1jdXdHblhCYTJod1l2bW55cXVLVzA5UlAzd3hCNTJ4NmVZSmNVNGVjMGhOc1REekZsMEUwdmQtREJiaERaUVlrU3lGcjlLbmtlNy1jSldOWDMtNA?oc=5" target="_blank">Egypt opens country’s first EIPICO 3 biologics and biosimilars plant</a>  <font color="#6f6f6f">Labmate Online</font>

Read Full StoryMore like this
Korean Biosimilars Target $400B Patent Cliff
조선일보general

Korean Biosimilars Target $400B Patent Cliff

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxQYXJucF9SMDhhb05kZEJaeHgtV0tNTTBNa21taVQ2VERjTjVQRC04Z3BJOUx0Vlh4Z1VaWVFjd0dzeTBRLXlnSjVPOGJ5eWkyU0dwOVQ0SnFtM2dWakk4a21XQl90aDdhLWhuM0JmN3lJZG9BM0k3OTJaaDJHV2t1YnpxOE5IdGwz?oc=5" target="_blank">Korean Biosimilars Target $400B Patent Cliff</a>  <font color="#6f6f6f">조선일보</font>

Read Full StoryMore like this
Biosimilar Firms Race for $400 Billion Patent Cliff
조선일보politics

Biosimilar Firms Race for $400 Billion Patent Cliff

<a href="https://news.google.com/rss/articles/CBMiiAFBVV95cUxOZEJsZU1fc1l6TTZPWDNiRTZUNnQ2TGlIWnhTT2JncU9ldzY3MjF2MnNNeFRoOGtnM0hoRVNXanBrNzMyYnV5SGNQR1l1b2VuTlZlcUNDSXhfU0wxdVNpUlhXWFZaT3ctb1NGY010Q3MwVHA1V1RmenBabmdQVUhzYVBoSGhOYjhQ?oc=5" target="_blank">Biosimilar Firms Race for $400 Billion Patent Cliff</a>  <font color="#6f6f6f">조선일보</font>

Read Full StoryMore like this
Biosimilars are driving down costs and increasing access to biologics
Managed Healthcare Executivegeneral

Biosimilars are driving down costs and increasing access to biologics

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOQWNiaWgwNlMwSW1NZWJNYmZYNTg4dU1Xa0Fud0ZrTW1XWENHRl91cldjeWp0NWJHNXotXzFZc2RQLU9sQ2haWFAtU05wSXdBQzBsZEJCYWJXeHdNdDg3QzlCNEp0RktuQmdmM2NaUjVmdzlqdXpTMDZVSnhVRGVrYlQwZmdsUWN3T0ViQklpUmI2NkZRajgzM0VOMWRjMWFjX19EU0tZSWpvX04tSUl2T2xObzRIUV96?oc=5" target="_blank">Biosimilars are driving down costs and increasing access to biologics</a>  <font color="#6f6f6f">Managed Healthcare Executive</font>

Read Full StoryMore like this
OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.
PR Newswiretech

OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.

<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxPenY1OElnOWJ5YWx4cWFkU2gwWnZSYzBrVmYxdVZUS1M3ckM4Sy1VWjJpMml6OGs0ZFZ1RE9hWHhVMDhONGlWLVNvRkxjZm1zZ3p2clVkQ2RMeDktV1BaMmw4UkxXbHd6ZHF6dWZWM1lsb1Q1MGZzT3JiY3FCdy1SSTNpVjJZSGZQWnlHSExJeF85SFYwQ0dTSGJkRFhYT1JtX25vMldGcWZHVlBpTU5FeWRZMWlrS0Q4Y0RXWU1EV1EwRkU5N2k2cHVlMG92VFkyUXhJa3Y4TlZyc3duY0Naa1dtTHRHTFpLcjUyd1pxV2NnRllZb3lleTJNNUhEM04xSG1UYTVoZXpNWXBjd2ItM0paaw?oc=5" target="_blank">OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®, now commercially available in the U.S.</a>  <font color="#6f6f6f">PR Newswire</font>

Read Full StoryMore like this
Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases
Business Wireworld

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases

<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxOc3NYWWFJY091OHdyVVMxbjhaRlpXeWxQX1JxMmt0QXRKYy00Tk9LbXpxODFyaWVqSHIxempwX3BaQzdyU1kyZzY3dHhBV1JyUHVMUFpTZDAwUzNieDlzcjNKVmtfM3hXbVU2QUYwV01EaFVCZzBEQkpiRWJvT0F5UnBiTEl5aXNoc2VlTXdsd2JscVJaSldYcWljNWRCV1VuREU1RTNfZnpNQ3FLaXU0YmVYaGgtQnJVNDkyRUVneTQ4eFBsUE81V3JNbnRTdkNYOFE3SEJWeVhSOG9vMVpfdUxmNmQ2TVdz?oc=5" target="_blank">Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases</a>  <font color="#6f6f6f">Business Wire</font>

Read Full StoryMore like this
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Yahoo Financeworld

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate

<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQZzlteF9mS1ZnVFZWSVdsNmFVNWtNZlBBZU13dml3MWljVG9razk1aDlrOFl3c0h3RnpWUXdWT3Z6b0pGVWIyWEFsT2R0VGtKNmVNTzVKd0N2ZVFCZlRTS0VNRmFFTV9SS3YxazhiSjNNTFRzUzNYX09Ob0FFQ0ViMUgtU3JBQlFTTE5XNEZ6NnVqQmxjbWcwSTVxUmxqS3c?oc=5" target="_blank">Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate</a>  <font color="#6f6f6f">Yahoo Finance</font>

Read Full StoryMore like this
SPONSORED Biosimilars, the healthcare hero in danger
Axiosscience

SPONSORED Biosimilars, the healthcare hero in danger

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9VRkZpYWllemItdmQ5Y1pvZS1zaXk4WTJMUkpEWFFxd1FGbUFBODdYa0NvcHZ4dGhLMTQ1OGFCZEVqNmFoSlJCZjh3T3h5Mm9ab1ljTmRzeHRacXFQWXJMSmVrV0FRdHZKZDhRLXJ1MlJoT2hyU18yUmhRRkxqUQ?oc=5" target="_blank">SPONSORED Biosimilars, the healthcare hero in danger</a>  <font color="#6f6f6f">Axios</font>

Read Full StoryMore like this
Could Faster Biosimilar Development Change the Economics of Biologic Drug Competition?
Kings Researchgeneral

Could Faster Biosimilar Development Change the Economics of Biologic Drug Competition?

<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5TLXlrWGdHbW9BTGo4RURPWkd0ZHVUczlSN01wWm1CaktUU2lpQmJJQVpzcW1zaXUzMVhQSFNtWDA0VkY4UWxyLXJ0ZkNtTWl1QnpMU1paemlHVEJaV29pWFdGMG45QzdrUnRUcnh0V3B5YzkyaGc?oc=5" target="_blank">Could Faster Biosimilar Development Change the Economics of Biologic Drug Competition?</a>  <font color="#6f6f6f">Kings Research</font>

Read Full StoryMore like this
"Biologics vs. Biosimilars" — Live Google News Trends & Headlines